HOPE Scientific studies
Study: Investigation into COVID-19 antibodies.
Collaborating parties: Swedish Royal Institute of Technology, the National Pandemic Centre at SciLifeLab, Karolinska Institutet and AstraZeneca.
Read more: https://www.iva.se/event/virusdetektion-och-antikroppstestning-av-covid-19—inblick-i-svenska-forskningslabb-och-spaning-framat/
Background and purpose
The purpose of this sub-study is to investigate the extent to which employees at AstraZeneca in Sweden have been exposed to the SARS-CoV-2 infection. Based on the results, the researchers seek to understand how the infection is spread in society. All employees will be offered a chance to take part in the sub-study and participation is entirely voluntary.
For an employee to be eligible to participate in the study, they must be invited by AstraZeneca and have a personal BankID and access to a smartphone.
The Swedish Royal Institute of Technology (KTH) is the responsible research body and responsible for the sub-study. KTH is conducting blood sample analysis and will then ensure that employees are notified of the results. ADDI Medical has been contracted by KTHfor the provision of the HOPE Corona platform.
Employees at AstraZeneca register for the sub-study via HOPE App, through which they receive ongoing information, appointments and test results. Through the app, employees are offered an automated information flow to help them to carry out the test step-by-step. Users are notified when it is time to perform a new activity.
A total of three blood tests are carried out over eight months. HOPE App also provides details of who employees can contact with any questions or for advice. Employees receive the results of their antibody test via HOPE App within one week.
HOPE Platform processes and shares user information in the sub-study a safe and secure manner with the support of consent under the GDPR.